Shumei Kato MD

PubMed

• PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome.
  Hui-Zi Chen, Na Hyun Kim, Daisuke Nishizaki, Mary K Nesline, Jeffrey M Conroy
  NPJ Genomic Medicine. 2025-03-11
• 1 citations
  Toll-like receptor 3: a double-edged sword.
  Marvin L Hsieh, Daisuke Nishizaki, Jacob J Adashek, Shumei Kato, Razelle Kurzrock
  Biomarker Research. 2025-02-23
• Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations.
  Jonathan Weitz, Daisuke Nishizaki, Joy Liau, Jay Patel, Isabella Ng
  Journal of Clinical Oncology. 2025-02-20

Journal Articles

• Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction and Gastric Adenocarcinoma  
  Lawrence Leichman, Jason K Sicklick, Shumei Kato, Kaitlyn Kelly, Scott M Lippman, Clinical Cancer Research

Lectures

• A functional measurement of MAPK pathway activation to predict response to MEK inhibitors in RAS-mutated patients. 
  2019 ASCO Annual Meeting - 6/1/2019
• PDL1 landscape in checkpoint inhibitor ineligible patients by IHC and cfRNA. 
  2019 ASCO Annual Meeting - 6/1/2019
• RAS alterations: Next-generation sequencing of 1,526 patients with diverse malignancies reveals prognostic and therapeutic correlates. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018